MBX Biosciences Inc

MBXNASDAQ · USD
59.12USD-2.86 (-4.63%)
2310

MBX Biosciences Inc (MBX) Implied Volatility Current

MBX implied volatility is 83%. IV Rank is 15%, placing current premiums in the bottom of their 52-week range.

Read more

Tracking MBX implied volatility helps you identify when options premiums on MBX Biosciences Inc are historically cheap or expensive, and where the best trades are hiding. MBX Biosciences Inc implied volatility reflects the market's expectation of future price movement: when MBX IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor MBX Biosciences Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For MBX, tracking metrics like MBX IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on MBX signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.

In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where MBX implied volatility sits today versus where it has been. Our scanner ranks MBX Biosciences Inc implied volatility against its historical range, surfaces extremes in MBX IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether MBX Biosciences Inc IV is rich or cheap — measure it, then act on it.

Implied Volatility

IV Rank
15.08%IV Rank
Low

IV is compressed vs the past year - options are relatively cheap, favoring buyers.

Implied Volatility (30d)83.14%

IV Rank15.08%

Historical Volatility (30d)35.46%

IV - HV+47.68%

As of September 22, 2026

Trade options with IV on your side

Track MBX IV rank across every expiration, spot where volatility is elevated, and identify high-probability setups before the window closes.

Start your 14-day free trial